Update of a systematic review and meta-analysis of the safety, effectiveness and efficacy of childhood schedules using Rotavirus vaccines

Overview

• 2 doses RV1 vaccine compared with placebo or no intervention probably results in little or no difference in all-cause mortality in low- and high-mortality countries (moderate-certainty evidence)
• 3 doses RV5 vaccine compared with placebo probably results in little or no difference in all-cause mortality in low- and high-mortality countries (moderate-certainty evidence)
• Rotasiil vaccine probably results in little or no difference in all-cause mortality compared with placebo (moderate certainty evidence)
• 3 doses Rotavac vaccine compared with placebo probably results in little or no difference in all-cause mortality (moderate-certainty evidence)
• There is a paucity of evidence on all-cause mortality for BRV-TV, LLR and Rotavin vaccines.
• It is uncertain whether 3 doses RV1 reduces all-cause mortality compared to 2 doses RV1 because the certainty of the evidence is very low.
• It is uncertain whether administering RV1 or RV5 at a younger age reduces all-cause mortality because the certainty of the evidence is very low.
• 2 doses RV1 administered with a shorter interval between doses may result in little or no difference in all-cause mortality compared to longer interval between doses (low-certainty evidence)
• It is uncertain whether administering RV1 or RV5 concomitantly with other childhood vaccines reduces all-cause mortality because the certainty of the evidence is very low.